Bokf Na Has $521,000 Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Bokf Na increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 4.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 15,400 shares of the company’s stock after purchasing an additional 690 shares during the quarter. Bokf Na’s holdings in Harmony Biosciences were worth $521,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after acquiring an additional 436 shares during the last quarter. Mendota Financial Group LLC lifted its stake in Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after purchasing an additional 965 shares during the last quarter. KBC Group NV grew its holdings in Harmony Biosciences by 79.9% during the fourth quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after purchasing an additional 819 shares during the period. PNC Financial Services Group Inc. raised its stake in Harmony Biosciences by 28.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company’s stock valued at $80,000 after buying an additional 519 shares during the period. Finally, Summit Investment Advisors Inc. lifted its position in shares of Harmony Biosciences by 34.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,987 shares of the company’s stock valued at $137,000 after buying an additional 1,029 shares during the last quarter. 86.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on HRMY shares. Mizuho boosted their target price on Harmony Biosciences from $42.00 to $44.00 and gave the stock an “outperform” rating in a report on Tuesday, March 18th. Needham & Company LLC reissued a “buy” rating and issued a $49.00 price objective on shares of Harmony Biosciences in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of Harmony Biosciences in a report on Tuesday, April 8th. Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a report on Tuesday, February 11th. They issued a “buy” rating and a $55.00 price target on the stock. Finally, UBS Group decreased their target price on Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating on the stock in a research report on Monday, April 28th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $52.33.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY opened at $34.05 on Friday. The business has a fifty day moving average price of $31.38 and a two-hundred day moving average price of $34.01. The stock has a market capitalization of $1.96 billion, a PE ratio of 16.14, a P/E/G ratio of 0.47 and a beta of 0.82. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $26.47 and a fifty-two week high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.19. The firm had revenue of $184.73 million for the quarter, compared to the consensus estimate of $184.26 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.67 earnings per share. As a group, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.